{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:52:48Z","timestamp":1781646768844,"version":"3.54.5"},"reference-count":23,"publisher":"Norwegian Medical Association","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2015,12,1]]},"DOI":"10.4045\/tidsskr.14.1478","type":"journal-article","created":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T04:12:21Z","timestamp":1449029541000},"page":"2052-8","source":"Crossref","is-referenced-by-count":3,"title":["Hepatitis C treatment at three Norwegian hospitals 2000\u20132011"],"prefix":"10.4045","volume":"135","author":[{"given":"Kjetil","family":"Isaksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Aabakken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore","family":"Grimstad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Karlsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Kristian","family":"Sandvei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Dalgard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Murphy DG, Sablon E, Chamberland J et al. Hepatitis C virus genotype 7, a new genotype originating from central Africa. J Clin Microbiol 2015; 53: 967\u2009\u2013\u200972. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25520447&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1128\/JCM.02831-14","DOI":"10.1128\/JCM.02831-14"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Dalgard O, Egeland A, Ervik R et al. Risikofaktorer for hepatitt C-smitte blant spr\u00f8ytemisbrukere. Tidsskr Nor Legeforen 2009; 129: 101\u2009\u2013\u20094. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19151801&dopt=Abstract","DOI":"10.4045\/tidsskr.09.35002"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Kielland KB, Delaveris GJ, Rogde S et al. Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: a longitudinal long-term cohort study. J Hepatol 2014; 60: 260\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24096048&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.jhep.2013.09.022","DOI":"10.1016\/j.jhep.2013.09.022"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Kielland KB, Skaug K, Amundsen EJ et al. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. J Hepatol 2013; 58: 31\u2009\u2013\u20097. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22960427&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.jhep.2012.08.024","DOI":"10.1016\/j.jhep.2012.08.024"},{"key":"ref=5","unstructured":"Bell H, Dalgard O, Bj\u00f8ro K et al. Behandling ved kronisk hepatitt C. Tidsskr Nor L\u00e6geforen 2002; 122: 926\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12082838&dopt=Abstract"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Strader DB, Wright T, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147\u2009\u2013\u200971. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15057920&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/hep.20119","DOI":"10.1002\/hep.20119"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975\u2009\u2013\u200982. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12324553&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa020047","DOI":"10.1056\/NEJMoa020047"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346\u2009\u2013\u200955. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14996676&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.7326\/0003-4819-140-5-200403020-00010","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Hansen N, Obel N, Christensen PB et al. Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study. BMC Infect Dis 2011; 11: 177. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21693019&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1186\/1471-2334-11-177","DOI":"10.1186\/1471-2334-11-177"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Toresen KH, Salte IM, Skrede S et al. Clinical outcomes in a cohort of anti-hepatitis C virus-positive patients with significant barriers to treatment referred to a Norwegian outpatient clinic. Scand J Gastroenterol 2014; 49: 465\u2009\u2013\u200972. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24472091&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3109\/00365521.2013.863965","DOI":"10.3109\/00365521.2013.863965"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878\u2009\u2013\u200987. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23607594&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa1214853","DOI":"10.1056\/NEJMoa1214853"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993\u2009\u2013\u20092001. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24795201&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa1316145","DOI":"10.1056\/NEJMoa1316145"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Dalgard O, Bj\u00f8ro K, Hellum KB et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 1260\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15558712&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/hep.20467","DOI":"10.1002\/hep.20467"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Dalgard O, Bj\u00f8ro K, Ring-Larsen H et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47: 35\u2009\u2013\u200942. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17975791&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/hep.21975","DOI":"10.1002\/hep.21975"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Lin ZH, Xin YN, Dong QJ et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726\u2009\u2013\u200936. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21319189&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/hep.24105","DOI":"10.1002\/hep.24105"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Dalgard O, Konopski Z, Bosse FJ et al. Hepatitt C- utredning og behandling. Tidsskr Nor Legeforen 2011; 131: 15. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21233879&dopt=Abstract","DOI":"10.4045\/tidsskr.10.02401"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Gidding HF, Law MG, Amin J et al. Hepatitis C treatment outcomes in Australian clinics. Med J Aust 2012; 196: 633\u2009\u2013\u20097. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22676878&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.5694\/mja12.10014","DOI":"10.5694\/mja12.10014"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Bourli\u00e8re M, Ouzan D, Rosenheim M et al. Pegylated interferon-\u03b12a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003\u2009\u2013\u20092007). Antivir Ther 2012; 17: 101\u2009\u2013\u200910. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22267474&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3851\/IMP1935","DOI":"10.3851\/IMP1935"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"McHutchison JG, Lawitz EJ, Shiffman ML et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580\u2009\u2013\u200993. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19625712&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa0808010","DOI":"10.1056\/NEJMx090031"},{"key":"ref=20","unstructured":"Felleskatalogen. Sovaldi. www.felleskatalogen.no\/medisin\/sovaldi-gilead-587507 (26.9.2015)."},{"key":"ref=21","unstructured":"Felleskatalogen. Pegasys. www.felleskatalogen.no\/medisin\/pegasys-roche-562679 (26.9.2015)."},{"key":"ref=22","unstructured":"Felleskatalogen. Copegus. www.felleskatalogen.no\/medisin\/copegus-roche-547649 (26.9.2015)."},{"key":"ref=23","unstructured":"Den norske legeforening. Faglig veileder for utredning og behandling av hepatitt C. www.hepatittfag.no (26.9.2015)."}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Hepatitt C-behandling ved tre norske sykehus 2000\u2009\u2013\u200911"],"language":"no","deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:00:47Z","timestamp":1781643647000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2015\/12\/originalartikkel\/hepatitt-c-behandling-ved-tre-norske-sykehus-2000-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,1]]},"references-count":23,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2015,12,1]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.14.1478","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,1]]}}}